Perspective on Potential Clinical Applications of Recombinant Human Interleukin‐7
- 14 December 2009
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1182 (1), 28-38
- https://doi.org/10.1111/j.1749-6632.2009.05075.x
Abstract
Interleukin‐7 has critical and nonredundant roles in T cell development, hematopoiesis, and postdevelopmental immune functions as a prototypic homeostatic cytokine. Based on a large body of preclinical evidence, it may have multiple therapeutic applications in immunodeficiency states, either physiologic (immuno‐senescence), pathologic (HIV) or iatrogenic (postchemotherapy and posthematopoietic stem cell transplant) and may have roles in immune reconstitution or enhancement of immunotherapy. Early clinical development trials in humans show that, within a short time, rhIL‐7 administration results in a marked preferential expansion of both naive and memory CD4 and CD8 T cell pools with a tendency toward enhanced CD8 expansion. As a result, lymphopenic or normal older hosts develop an expanded circulating T cell pool with a profile that resembles that seen earlier in life with increased T cell repertoire diversity. These results, along with a favorable toxicity profile, open a wide perspective of potential future clinical applications.Keywords
This publication has 67 references indexed in Scilit:
- IL-7 administration drives T cell–cycle entry and expansion in HIV-1 infectionBlood, 2009
- Enhanced T cell recovery in HIV-1–infected adults through IL-7 treatmentJCI Insight, 2009
- Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsetsThe Journal of Experimental Medicine, 2008
- CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cellsThe Journal of Experimental Medicine, 2006
- Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cellsThe Journal of Experimental Medicine, 2006
- IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory CellsJournal of Immunotherapy, 2006
- Dysregulation of T-Cell Function in the ElderlyDrugs & Aging, 2005
- Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapyBlood, 2005
- Interleukin-7: a Cofactor For V(D)J Rearrangement of the T Cell Receptor β GeneScience, 1993
- Development of lymphocytes in interleukin 7‐transgenic miceEuropean Journal of Immunology, 1991